What does semaglutide cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| Savings offer for Wegovy with commercial insurance | From $25per month | When a commercial plan covers the prescription, the manufacturer savings offer lets eligible patients pay as little as $25 per month, subject to a maximum savings of $100 per month, so the final cost depends on the plan copay (checked 2026-09-22). Government beneficiaries are excluded from the savings offer. Many employer plans exclude weight management drugs while covering Ozempic for type 2 diabetes, and standard Medicare Part D coverage does not extend to drugs prescribed only for weight loss; the separate Medicare GLP-1 Bridge row covers that case. [7] [8] [15] |
| Medicare GLP-1 Bridge | $50per month | Under the Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026 to December 31, 2027, eligible adults with Medicare Part D pay a $50 copay for a one-month supply of Wegovy injection or tablets prescribed for weight management (checked 2026-09-22). Eligibility is set by BMI and qualifying conditions, prior authorization is required, and people with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease are excluded because their Part D plan may cover a GLP-1 instead. The copay does not count toward the Part D deductible or out-of-pocket limit. [13] [14] [18] |
| List price (Wegovy, Ozempic, Rybelsus) | $1,028 to $1,349per month | Manufacturer list price (wholesale acquisition cost) for a one-month supply before insurance, checked 2026-09-22: $1,027.51 for Ozempic pens and tablets and for Rybelsus tablets, and $1,349.02 for Wegovy pens and tablets, the same at every dose strength. The manufacturer announced on February 24, 2026 that these list prices fall to $675 per month on January 1, 2027. Retail pharmacies may add a margin. [1] [2] [3] [4] |
| Self-pay Wegovy and Ozempic | $149 to $499per month | Manufacturer direct-to-patient self-pay prices for branded semaglutide, checked 2026-09-22. Wegovy tablets: $149 per month at 1.5 mg, 199 at 4 mg, 299 at 9 mg and 25 mg. Wegovy pen: $349 per month from 0.25 mg to 2.4 mg ($199 for the first two monthly fills of 0.25 mg and 0.5 mg for new patients, through December 31, 2026) and $399 for the 7.2 mg dose. Ozempic tablets: $149 to $299 per month by dose. Ozempic pen: $349 per month at 0.25 mg to 1 mg and $499 at 2 mg ($199 for the first two monthly fills of 0.25 mg and 0.5 mg for new patients, through December 31, 2026). The manufacturer says the 2027 list price cut does not change these self-pay prices. [4] [5] [6] [7] |
| Telehealth program | $223 to $548per month | A licensed telehealth provider's published price, checked 2026-09-22: a program membership of $74 per month on an annual prepaid plan up to $149 on a month-to-month plan ($39 for the first month), plus branded semaglutide billed at the manufacturer self-pay price (Wegovy tablets from $149, Wegovy pen $199 to $399 per month). Membership plus medication comes to about $223 to $548 per month. Members who use insurance for the drug pay the membership on top of the plan copay. [5] [12] |
| Compounded pharmacy (2024 survey) | $189 to $294per month | Historical price from a peer-reviewed study of 79 websites selling compounded semaglutide, searched July to September 2024 during the shortage: median first-month price $231, interquartile range $189 to $294, including discounts. No current dated lawful price was found. Since the FDA 503A grace period ended on April 22, 2025, compounded semaglutide is limited to documented patient specific needs, and on March 3, 2026 the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms. [9] [10] [11] [16] [17] |
What is the list price of semaglutide?
List prices are manufacturer wholesale acquisition costs for a one-month supply and are the same at every dose strength: $1,027.51 for Ozempic and Rybelsus and $1,349.02 for Wegovy at the verification date. The manufacturer has announced a single list price of $675 per month for these products from January 1, 2027. Self-pay prices are far below list because they bypass pharmacy benefit managers.
Which insurance covers Wegovy and Ozempic?
Coverage depends on the indication on the prescription. Type 2 diabetes (Ozempic) is widely covered; chronic weight management (Wegovy) is excluded by many employer plans and by Medicare Part D when prescribed for weight loss alone, although the cardiovascular risk reduction indication has opened coverage for some patients with established heart disease. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge demonstration covers Wegovy for weight management at a $50 monthly copay for eligible Part D enrollees. The manufacturer savings offer applies to commercial insurance only. Separately, semaglutide (Ozempic, Rybelsus, Wegovy) was selected for Medicare drug price negotiation. From January 1, 2027, Medicare Part D uses a negotiated price that CMS reports as $274 for a 30 day supply, 71% below the 2024 list price; the negotiated price per package varies by product and strength, for example about $385 for a four-pen carton of the highest Wegovy dose (CMS, announced November 2025). This is the price Medicare and pharmacies work from, not the enrollee's copay, which still depends on the plan's cost sharing and on whether the drug is covered for the prescribed indication.
What changes the price?
- Whether the prescription is for a covered indication (type 2 diabetes, cardiovascular risk reduction) or for weight loss alone
- List price versus manufacturer self-pay price versus a commercial plan copay with the savings offer
- Dose strength: list price is flat across doses, but self-pay prices rise from the starting doses to the 2 mg Ozempic and 7.2 mg Wegovy doses
- Tablet versus pen, since the lowest tablet doses have the lowest self-pay price
- Telehealth membership fees charged on top of the drug
- The announced January 1, 2027 list price reduction, which matters most for high-deductible and coinsurance plans
Frequently asked questions
How much does semaglutide cost without insurance?
About $149 to $1,349 per month at the verification date, depending on the channel: list price (Wegovy, Ozempic, Rybelsus), self-pay Wegovy and Ozempic, compounded pharmacy (2024 survey), telehealth program. See the table above for what each figure includes. [1] [2] [3] [4] [5] [6] [7] [9] [10] [11] [12] [16] [17]
Does insurance cover semaglutide?
Coverage depends on the indication on the prescription. Type 2 diabetes (Ozempic) is widely covered; chronic weight management (Wegovy) is excluded by many employer plans and by Medicare Part D when prescribed for weight loss alone, although the cardiovascular risk reduction indication has opened coverage for some patients with established heart disease. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge demonstration covers Wegovy for weight management at a $50 monthly copay for eligible Part D enrollees. The manufacturer savings offer applies to commercial insurance only. Separately, semaglutide (Ozempic, Rybelsus, Wegovy) was selected for Medicare drug price negotiation. From January 1, 2027, Medicare Part D uses a negotiated price that CMS reports as $274 for a 30 day supply, 71% below the 2024 list price; the negotiated price per package varies by product and strength, for example about $385 for a four-pen carton of the highest Wegovy dose (CMS, announced November 2025). This is the price Medicare and pharmacies work from, not the enrollee's copay, which still depends on the plan's cost sharing and on whether the drug is covered for the prescribed indication. [7] [8] [13] [14] [15] [18]
What is the list price of semaglutide?
List prices are manufacturer wholesale acquisition costs for a one-month supply and are the same at every dose strength: $1,027.51 for Ozempic and Rybelsus and $1,349.02 for Wegovy at the verification date. The manufacturer has announced a single list price of $675 per month for these products from January 1, 2027. Self-pay prices are far below list because they bypass pharmacy benefit managers. [1] [2] [3] [4] [5] [6] [7]
Related pages
- Semaglutide: evidence, legality, and access
- AOD-9604 vs semaglutide (AOD-9604 cost)
- Semaglutide vs cagrilintide
- Semaglutide vs dulaglutide (Dulaglutide cost)
- Semaglutide vs exenatide (Exenatide cost)
- Semaglutide vs liraglutide (Liraglutide cost)
- Semaglutide vs mazdutide
- Semaglutide vs retatrutide (Retatrutide cost)
- Semaglutide vs setmelanotide
- Semaglutide vs survodutide
- Semaglutide vs tirzepatide (Tirzepatide cost)
- Tesofensine vs semaglutide (Tesofensine cost)
- Obesity and chronic weight management: peptide evidence
- Type 2 diabetes: peptide evidence
- Longevity and healthy aging: peptide evidence
- Cardiovascular risk reduction: peptide evidence
- Chronic kidney disease: peptide evidence
- Fatty liver disease (MASLD and MASH): peptide evidence
- Fat loss and body composition: peptide evidence
- Osteoarthritis: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- Wegovy pill vs injection: what the trials show
Semaglutide now comes as a daily tablet and a weekly injection for weight management. We compare the trials, the label differences, and what each costs to get.
- What happened to compounded semaglutide
Compounded semaglutide went from a shortage workaround to a narrow, patient-specific exception. Here is the timeline, what FDA found, and what access looks like in 2026.
- Do GLP-1 patches work? What they contain and what the evidence says
No FDA-approved GLP-1 patch exists. Here is why GLP-1 drugs cannot pass through skin from a sticker, what patch ingredients have been tested by mouth, and how to read patch reviews.
- GLP-1 supplements vs GLP-1 drugs: what GLP-1 boosters actually do
Berberine, fiber, and probiotics sold as GLP-1 boosters are not GLP-1 drugs. Here is the human evidence for each ingredient, graded, and how it compares with semaglutide and tirzepatide.
- Microdosing GLP-1s and tirzepatide: what the evidence says
No trial has tested microdosing semaglutide or tirzepatide. What the labels say about dose steps and why they exist, FDA's dosing-error warnings, and what to ask a prescriber.
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
More on the blog
Sources
- [1]Manufacturer list price (wholesale acquisition cost) page for semaglutide for weight management, pens and tablets, accessed 2026-09-222026
- [2]Manufacturer list price (wholesale acquisition cost) page for semaglutide injection and tablets for type 2 diabetes, accessed 2026-09-222026
- [3]Manufacturer list price (wholesale acquisition cost) page for oral semaglutide tablets for type 2 diabetes, accessed 2026-09-222026
- [4]Manufacturer press release: semaglutide list price lowered to $675 per month effective January 1, 2027, self-pay prices unchanged (February 24, 2026)2026
- [5]Manufacturer direct-to-patient pharmacy page with semaglutide self-pay and commercial savings prices, accessed 2026-09-222026
- [6]Manufacturer self-pay price guide for semaglutide for weight management, pens and tablets, accessed 2026-09-222026
- [7]Manufacturer self-pay and commercial copay price guide for semaglutide for type 2 diabetes, pens and tablets, accessed 2026-09-222026
- [8]Manufacturer savings offer terms for semaglutide for weight management (commercial insurance and self-pay), accessed 2026-09-222026
- [9]Online advertising of compounded glucagon-like peptide-1 receptor agonists (JAMA Health Forum, 2025): cross-sectional study of 79 websites with first-month pricesPubMed 39820389, 2025
- [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA